GPC3 and hepatocellular carcinoma: Phase I/II clinical trials suggested that GPC3 peptide vaccine is effective in inducing cytotoxic T lymphocyte (CTL) killing cancer cells, reducing RFS, and improving OS, particularly in patients with GPC3-overexpressing HCC (105, 108, 109).